Trial · NCT03843775

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

NCT03843775, Phase 1, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2024-10-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers. Trials, record NCT03843775. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03843775

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
NCT number: NCT03843775
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 17 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Advanced BRAF Mutant Cancers
Interventions: Binimetinib, Encorafenib
First posted: 2019-02-18
Last updated: 2024-10-21
Results first posted: 2024-10-21

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Dose-limiting Toxicities (DLTs)	1 year	National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5,
Primary	Objective Response Rate (Phase II)	1 year	Per RECIST Version 1.1

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Dose-limiting Toxicities (DLTs)	1 year	DLTs only evaluated for Dose Level 1 cohort	DLTs	NUMBER
PRIMARY	Objective Response Rate (Phase II)	1 year	ORR was only assessed for the Dose Level 2 group	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Dose-limiting Toxicities (DLTs)	Dose Level 1		0		DLTs
Objective Response Rate (Phase II)	Dose Level 2		6.7	95% Confidence Interval 0.3 to 31.9	percentage of participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dose Level 1	4
Overall Study	STARTED	Dose Level 2	13
Overall Study	COMPLETED	Dose Level 1	1
Overall Study	COMPLETED	Dose Level 2	5
Overall Study	NOT COMPLETED	Dose Level 1	3
Overall Study	NOT COMPLETED	Dose Level 2	8

Source ClinicalTrials.gov

Adverse events74

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	Dose Level 1	1	4
other	Nausea	Gastrointestinal disorders	Dose Level 2	7	13
other	Gastrointestinal hemorrhage	Gastrointestinal disorders	Dose Level 1	1	4
other	Gastrointestinal hemorrhage	Gastrointestinal disorders	Dose Level 2	2	13
other	Blurred vision	Eye disorders	Dose Level 1	1	4
other	Blurred vision	Eye disorders	Dose Level 2	1	13
other	Diarrhea	Gastrointestinal disorders	Dose Level 1	2	4
other	Diarrhea	Gastrointestinal disorders	Dose Level 2	4	13
other	Dry eye	Eye disorders	Dose Level 1	1	4
other	Dry eye	Eye disorders	Dose Level 2	0	13

1 to 10 of 74Source ClinicalTrials.gov

See all 74 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dose Level 1	4	4
Total, all-cause mortality	Dose Level 2	12	13
Total, other adverse events	Dose Level 1	4	4
Total, other adverse events	Dose Level 2	13	13
Total, serious adverse events	Dose Level 1	1	4
Total, serious adverse events	Dose Level 2	3	13

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
35385748	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Dose Level 1 vs Dose Level 2: deaths from any cause	Trial comparisons
Dose Level 1 vs Dose Level 2: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03843775

GET https://conductscience.org/api/trials/v1/NCT03843775/events?page=2

API reference For AI assistants